Cancer Clinical Trial Education for Primary Care Providers serving Asian American Communities
1. DO YOU KNOW…
- Participation in a cancer clinical trial may be a high quality treatment option for your patients? 1
- Although 20% are eligible, less than 5% of adult cancer patients take part in clinical trials-and that the numbers are even fewer among minorities and medically under served populations? 2,3,4,5,6
- A physician’s recommendation is often the primary factor influencing patients’ decisions to enroll in a trial? 7,8
- Only 2% of primary care providers routinely discuss oncology trials with their patients?9
2. WHO SHOULD BE TRAINED?
3. PURPOSE OF THIS COURSE
- To educate primary care providers about cancer clinical trials
- To provide information and resources for primary care providers on the available cancer clinical trials
4. LEARNING OBJECTIVE
By the end of this course, participants will be able to:
- Define cancer clinical trials, including how they work and their risks and benefits
- Identify common patient barriers to cancer clinical trials participation
- Understand barriers faced by health care providers to making referrals, and explore ways in which these barriers can be overcome
- Understand the importance of health care providers being the first point of contact for patient participation in clinical trials
- Advise patients where to find available cancer clinical trials in local areas
- Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to sponsor Continuing Medical Education for physicians
- Temple University School of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity
6. DOWNLOADS AND ADDITIONAL RESOURCES
Course flyer (click this link to download)
Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002 Apr 15;20(8):2109-17.
Christian MC, Trimble EL. Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):277s-283s.
National Cancer Institute, 2002 https://accrualnet.cancer.gov/sites/accrualnet.cancer.gov/files/ResourceGuide_Book_m.pdf
Brawley, O. (2004). The study of accrual to clinical trials: Can we learn from studying who enters our studies? Journal of Clinical Oncology, 22(11), 2039-2040.
Murthy VH, Krumholz HM, Gross CP.Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 Jun 9;291(22):2720-6.
Comis, R. L., Aldige CR, Stovall EL, Krebs LU, Risher Peter J, Taylor HJ A quantitative survey of public attitudes towards cancer clinical trials [On-line]. 2000. Available at http://www.cancertrialshelp.org/CTHpdf/308-9.pdf
Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E.Public attitudes toward participation in cancer clinical trials. Journal of Clinical Oncology.2003; 21: 830-835.
Crosson, K., Eisner, E., Brown, C., & Ter Maat, J. (2001). Primary care physicians’ attitudes, knowledge, and practices related to cancer clinical trials. J Canc Educ,16(4), 188-192.